NDAORALTABLET, EXTENDED RELEASE
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
MINOLIRA (minocycline hydrochloride) by Fosun Pharma is 12. Approved for ischemic stroke, acute, rosacea, peripheral neuropathy and 3 more indications. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINOLIRA is an oral extended-release tablet containing minocycline hydrochloride, a tetracycline antibiotic approved in 2017 for acne and indicated for multiple conditions including rosacea, acute ischemic stroke, traumatic brain injury, peripheral neuropathy, breast cancer, and acute pain. The mechanism of action for acne treatment remains unknown, though minocycline is lipid-soluble and distributes into skin and sebum.
Peak9.9 years to LOE
MINOLIRA is in peak commercial phase with 10 years of patent protection remaining, suggesting a stable team supporting a mature product line.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of MINOLIRA for the treatment of acne is unknown. 12.2 Pharmacodynamics The pharmacodynamics of MINOLIRA for the treatment of acne are unknown. 12.3 Pharmacokinetics The pharmacokinetics of minocycline following oral administration of a single dose…
Indications (6)
Investigational (6)
Worked on MINOLIRA at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.